-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the beginning of this year, senior executives of domestic and foreign pharmaceutical companies have left their jobs very frequently
.
According to statistics, in the first half of the year, 128 senior executives in the pharmaceutical industry have resigned, a year-on-year decrease of about 20% compared with about 160 senior executives of pharmaceutical companies in the first half of 2020
.
It is worth noting that this wave of departures has continued since December, and many pharmaceutical companies have successively announced new executive appointments
.
Recently, it has been reported that the current CEO Dr.
Huaqiong Shen will leave due to personal reasons.
The working day of the company will end on December 31
.
After his resignation, Dr.
Zang Jingwu will serve as the acting CEO of Tianjing Biology from January 1, 2022
.
It is worth noting that when the news of Dr.
Shen Huaqiong's resignation broke out this time, Tianjing Biological also reported a number of senior management personnel changes
.
Including the appointment of Dr.
Zhu Xiuxuan, an internationally renowned oncology expert, as the president and director of Tianjing Bio; and the appointment of Mr.
Long Jiang, a senior industry expert, as the chief financial officer (CFO) of Tianjing Bio, and joining the company's board of directors
.
The former CFO Mr.
Zhu Jielun was transferred to Chief Strategy Officer (CSO), focusing on planning and advancing corporate development strategies, major corporate strategic projects and early-stage venture capital
.
It is worth noting that, in addition to the successive announcements of senior management changes by Tianjing Biotechnology, according to incomplete statistics, since December, many senior executives in the pharmaceutical industry have also resigned
.
For example, on December 9th, AstraZeneca formally announced to employees that Yin Min of AstraZeneca's Chinese Oncology Division and Wang Dong, head of the Retail Division, have decided to leave AstraZeneca to seek external career development opportunities.
The two are working in AZ.
Will end on the 31st of this month
.
On December 3, Hebo Medicine announced that it had formally appointed Xu Weihao as Chief Strategy Officer, reporting directly to Dr.
Wang Jinsong, the founder, chairman and CEO of Hebo Medicine
.
As the global head of the company’s business development and corporate development, Xu Weihao will be responsible for the formulation of strategies, innovation capabilities, and innovation ecosystem construction for Hebo Pharmaceuticals to promote the company’s development
.
At the same time, he will also participate in the company's product line strategy and the expansion of investor relations in the international market
.
On December 2, Fresenius Kabi issued an internal notice: Mr.
Ding Weibo, President of Feka China, has decided to accept external development opportunities and will officially leave on February 1, 2022
.
It is reported that Mr.
UlfJansson, Executive Vice President of Fresenius Kabi Asia Pacific, will concurrently serve as the President of Fresenius Kabi China, and will complete the handover with Mr.
Ding Weibo before the end of January next year
.
According to incomplete statistics in the industry, including the above companies, over 200 senior executives in the pharmaceutical industry have left since the beginning of the year
.
Among them, the deputy general managers and directors resign intensively, and the reasons for resignation are mainly "personal reasons"
.
On the whole, it is clear that the resignation of senior executives in the pharmaceutical industry has become the norm
.
The industry predicts that the entire domestic pharmaceutical industry is currently facing greater pressure from medical insurance control fees; and the epidemic has affected the R&D, clinical and sales stages of pharmaceutical companies, and pharmaceutical companies will continue to respond to market changes.
Adjust the development plan, this will also lead to the continued acceleration of the flow of talents in the pharmaceutical market in the future
.
.
According to statistics, in the first half of the year, 128 senior executives in the pharmaceutical industry have resigned, a year-on-year decrease of about 20% compared with about 160 senior executives of pharmaceutical companies in the first half of 2020
.
It is worth noting that this wave of departures has continued since December, and many pharmaceutical companies have successively announced new executive appointments
.
Recently, it has been reported that the current CEO Dr.
Huaqiong Shen will leave due to personal reasons.
The working day of the company will end on December 31
.
After his resignation, Dr.
Zang Jingwu will serve as the acting CEO of Tianjing Biology from January 1, 2022
.
It is worth noting that when the news of Dr.
Shen Huaqiong's resignation broke out this time, Tianjing Biological also reported a number of senior management personnel changes
.
Including the appointment of Dr.
Zhu Xiuxuan, an internationally renowned oncology expert, as the president and director of Tianjing Bio; and the appointment of Mr.
Long Jiang, a senior industry expert, as the chief financial officer (CFO) of Tianjing Bio, and joining the company's board of directors
.
The former CFO Mr.
Zhu Jielun was transferred to Chief Strategy Officer (CSO), focusing on planning and advancing corporate development strategies, major corporate strategic projects and early-stage venture capital
.
It is worth noting that, in addition to the successive announcements of senior management changes by Tianjing Biotechnology, according to incomplete statistics, since December, many senior executives in the pharmaceutical industry have also resigned
.
For example, on December 9th, AstraZeneca formally announced to employees that Yin Min of AstraZeneca's Chinese Oncology Division and Wang Dong, head of the Retail Division, have decided to leave AstraZeneca to seek external career development opportunities.
The two are working in AZ.
Will end on the 31st of this month
.
On December 3, Hebo Medicine announced that it had formally appointed Xu Weihao as Chief Strategy Officer, reporting directly to Dr.
Wang Jinsong, the founder, chairman and CEO of Hebo Medicine
.
As the global head of the company’s business development and corporate development, Xu Weihao will be responsible for the formulation of strategies, innovation capabilities, and innovation ecosystem construction for Hebo Pharmaceuticals to promote the company’s development
.
At the same time, he will also participate in the company's product line strategy and the expansion of investor relations in the international market
.
On December 2, Fresenius Kabi issued an internal notice: Mr.
Ding Weibo, President of Feka China, has decided to accept external development opportunities and will officially leave on February 1, 2022
.
It is reported that Mr.
UlfJansson, Executive Vice President of Fresenius Kabi Asia Pacific, will concurrently serve as the President of Fresenius Kabi China, and will complete the handover with Mr.
Ding Weibo before the end of January next year
.
According to incomplete statistics in the industry, including the above companies, over 200 senior executives in the pharmaceutical industry have left since the beginning of the year
.
Among them, the deputy general managers and directors resign intensively, and the reasons for resignation are mainly "personal reasons"
.
On the whole, it is clear that the resignation of senior executives in the pharmaceutical industry has become the norm
.
The industry predicts that the entire domestic pharmaceutical industry is currently facing greater pressure from medical insurance control fees; and the epidemic has affected the R&D, clinical and sales stages of pharmaceutical companies, and pharmaceutical companies will continue to respond to market changes.
Adjust the development plan, this will also lead to the continued acceleration of the flow of talents in the pharmaceutical market in the future
.
